Answers are grounded in this paper and cite their sources.
Inhibitors demonstrate improved selectivity targeting WRN helicase in MSI-H cancers, suggesting new cancer therapies.
Recent advances targeting WRN helicase highlight a promising synthetic lethality approach for treating microsatellite instability-high (MSI-H) cancers. GlaxoSmithKline and Moma Therapeutics independently developed small molecule inhibitors with distinct chemotypes that disrupt WRN function. Their complementary efforts showcase differentiated selectivity, strategic molecular designs, and a shared focus on exploiting WRN dependency in DNA mismatch repair-deficient tumors.
No takes yet. Share an insight, caveat, or question.
Robert B. Kargbo (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: